Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer.

ABSTRACT:

Background

There are robust data supporting the contribution of oxaliplatin (L-OHP) regarding clinical outcomes for colorectal cancer (CRC) in an adjuvant setting in European and US trials; however, there is no Japanese clinical evidence although L-OHP has been approved since 2009. We examined the transition of adjuvant chemotherapy for stage III colorectal cancer in our institute.

Methods

A total of 642 patients with histopathologically confirmed stage III CRC underwent curative surgery from 2005 to 2010. We examined disease free survival (DFS), overall survival (OS) and prognostic factors for stage III CRC patients who underwent adjuvant chemotherapy.

Results

A total of 509 patients received adjuvant chemotherapy. 3-year DFS and 5-year OS rates were 74.5% and 87.5%,

SUBMITTER: Osumi H 

PROVIDER: S-EPMC5451009 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature